Mahindra Manulife Multi Cap Fund
The scheme seeks to provide medium to long term capital appreciation through appropriate diversification and taking low risk on business quality.
Growthvine rating: 5/5 — ranked #3 of 34 in category.
Fund basics
| Category | Equity: Multi Cap |
|---|
| NAV | ₹40.04 (as of 2026-11-13) |
|---|
| AUM | ₹7,457 Cr |
|---|
| Expense ratio | 1.54% |
|---|
| Riskometer | Very High |
|---|
| Fund manager | Neelesh Dhamnaskar |
|---|
| Exit load | 1% for redemption within 3 months |
|---|
Performance & risk
| 5-year annualised return | 11.90% |
|---|
| Sharpe ratio | 0.55 |
|---|
| Standard deviation | 16.99% |
|---|
| Max drawdown | −34.53% |
|---|
| Alpha | 5.49 |
|---|
| Beta | 0.96 |
|---|
Over 5 years, captured 104.3% of NIFTY500 Multicap 50:25:25's upside and 96.6% of its downside.
Market cap allocation
| Large cap | 46.5% |
|---|
| Mid cap | 28.9% |
|---|
| Small cap | 24.6% |
|---|
Concentration
| Top 5 holdings | 17.6% |
|---|
| Top 10 holdings | 30.4% |
|---|
| Total holdings | 72 |
|---|
| Index overlap | 28.4% |
|---|
| Active share | 71.6% |
|---|
Top holdings
- Divis Laboratories Ltd. — 5.4%
- ICICI Bank Ltd. — 3.5%
- Reliance Industries Ltd — 3.0%
- Multi Commodity Exchange of India Ltd — 2.9%
- BSE Ltd. — 2.9%
- HDFC Bank Ltd. — 2.8%
- Neuland Laboratories Limited. — 2.6%
- Oil India Limited — 2.5%
- Adani Enterprises Ltd. — 2.5%
- Torrent Pharmaceuticals Ltd. — 2.3%
Top sectors
- Banking & Financial — 20.5%
- Pharma & Biotech — 14.8%
- Industrial Products — 8.4%
Calendar-year track record
| Year | Return | Quartile | Category rank |
|---|
| 2026 (partial) | 11.2% | Q1 (Top) | #6 of 33 |
| 2025 | 3.4% | Q2 | #14 of 30 |
| 2024 | 23.4% | Q2 | #11 of 23 |
| 2023 | 34.2% | Q2 | #7 of 16 |
| 2022 | 1.6% | Q3 | #8 of 12 |